[(pF)Phe4]Nociceptin(1-13)NH2
CAS No. 380620-88-2
[(pF)Phe4]Nociceptin(1-13)NH2( —— )
Catalog No. M30623 CAS No. 380620-88-2
Highly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotropic and feeding stimulation effects in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name[(pF)Phe4]Nociceptin(1-13)NH2
-
NoteResearch use only, not for human use.
-
Brief DescriptionHighly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotropic and feeding stimulation effects in vivo.
-
DescriptionHighly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotropic and feeding stimulation effects in vivo.
-
In Vitro——
-
In VivoIn unanaesthetised normotensive mice, bolus intravenous injection of 100 nmol/kg of [(pF)Phe4]Nociceptin(1-13)NH2 decreases mean blood pressure and heart rate; these effects are longer lasting than those elicited by the same dose of NC(1-13)NH2. I.c.v. administration of [(pF)Phe4]Nociceptin(1-13)NH2 dose-dependently stimulated feeding in rats, and is about tenfold more potent than NC(1-13)NH2.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetOpioid Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number380620-88-2
-
Formula Weight1399.6
-
Molecular FormulaC61H99FN22O15
-
Purity>98% (HPLC)
-
Solubilitywater:2 mg/mL
-
SMILES[H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=C(F)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bigoni et al (2002) Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies. Naunyn Schmiedebergs Arch.Pharmacol. 365 442 PMID:
molnova catalog
related products
-
Salvinorin A
Salvinorin A is a non-nitrogenous κ-opioid selective agonist.
-
LY-2940094
LY-2940094 decreases ethanol self-administration in animal models.
-
Hemorphin-7
Hemorphin-7 binds to the angiotensin IV receptor, triggering multiple effects including cellular proliferation and memory enhancement. Hemorphins are endogenous peptides belonging to the family of atypical opioid peptides released from hydrolyzed hemoglobin. Hemorphin-7 is investigated as a potential biomarker for breast cancer.
Cart
sales@molnova.com